<DOC>
	<DOCNO>NCT00266110</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell may help body build effective immune response kill tumor cell . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , vinorelbine , work different way stop growth tumor cell , either kill cell stop divide . Giving vaccine therapy together trastuzumab vinorelbine may kill tumor cell . PURPOSE : This phase II trial study well give vaccine therapy together trastuzumab vinorelbine work treat patient locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Vaccine Therapy , Trastuzumab , Vinorelbine Treating Patients With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy multiepitope autologous dendritic cell vaccine combination trastuzumab ( Herceptin® ) vinorelbine ditartrate patient locally recurrent metastatic breast cancer whose tumor overexpress HER2/neu . Secondary - Determine regimen effective generate functional antigen-specific T cell . OUTLINE : - Therapeutic autologous dendritic cell ( DC ) preparation : Patients undergo mobilization DC apheresis production therapeutic DC . DCs expand vitro 10-20 day pulse E75 E90 peptide . - Treatment : Patients receive vinorelbine ditartrate IV 6-10 minute , therapeutic autologous DC intradermally 2-5 minute , trastuzumab ( Herceptin® ) IV 30-90 minute day 1 . Patients receive sargramostim ( GM-CSF ) subcutaneously day 2 , 4 , 6 , neutrophil count recover . Treatment repeat every 14 day 6 course ( discretion investigator ) absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>PATIENT ELIGIBILITY 4.1 Inclusion Criteria 4.1.1 Histologically proven metastatic breast cancer measurable evaluable disease per investigator discretion . 4.1.2 Patients must 18 year age old . Women child bear potential must practice barrier oral contraception duration study , document surgically sterile one year postmenopausal . 4.1.3 ECOG performance status 02 ( See Appendix A ) . 4.1.5 Cardiac function MUGA EF &gt; 45 % echocardiogram show normal LV function . 4.1.6 Serum Creatinine &lt; 2.0 mg/dl . 4.1.7 Hepatic transaminase ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ) ≤3.0 time upper limit normal liver metastases ≤5 time upper limit normal liver metastasis present . 4.1.8 Bilirubin 2X normal . 4.1.9 Seronegative HIV . 4.1.10 Negative Hepatitis B surface antigen . 4.1.11 Signed date informed consent . 4.1.12 HLA A0201+ DNA genotyping . 4.1.13 Absolute neutrophil count great 1,500/mm3 . Platelet count great 100,000/mm3 hemoglobin great equal 10 4.1.14 . 3+ expression HER2/neu original pathology ( diagnostic ) tumor sample IHC 2+ expression IHC gene amplification FISH . 4.1.15 . Patients eligible even fail treatment metastatic breast cancer trastuzumab chemotherapy agent vinorelbine progress within 12 month receive adjuvant chemotherapy use trastuzumab taxane . 4.2 Exclusion Criteria 4.2.1 Patients serious medical , cardiac , psychiatric condition , opinion investigator , would make patient unsuitable study participation would impede probable compliance protocol . 4.2.2 Patients central nervous system metastasis must stable disease least 3 month prior study entry . 4.2.3 Patient currently take steroid medication . Systemic steroid treatment allow . 4.2.4 Patients fail prior therapy vinorelbine + trastuzumab eligible therapy . 4.2.5 Patient receive hormonal cytotoxic chemotherapy within 14 day apheresis within 2830 day prior study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>